Exane Derivatives Phathom Pharmaceuticals, Inc. Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Exane Derivatives holds 11,141 shares of PHAT stock, worth $203,546. This represents 0.06% of its overall portfolio holdings.
Number of Shares
11,141
Previous 5,874
89.67%
Holding current value
$203,546
Previous $79,000
18.99%
% of portfolio
0.06%
Previous 0.02%
Shares
8 transactions
Others Institutions Holding PHAT
# of Institutions
124Shares Held
59MCall Options Held
467KPut Options Held
34.9K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$185 Million6.14% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$136 Million28.04% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$63.9 Million4.3% of portfolio
-
Invesco Ltd. Atlanta, GA3.14MShares$57.4 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.93MShares$53.5 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $716M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...